A phase 1b/2, open-label study of amivantamab monotherapy or in combination with standard-of-care chemotherapy in participants with advanced or metastatic colorectal cancer. This is an ASCO Meeting ...
A first-in-human phase Ia/b, open-label, multicenter study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers. Background: Patients with advanced colorectal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results